FindTrial
Sign In

CY

DRUG7 trials

Sponsors

Stanford University, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Oncotherapeutics, Jinan Military General Hospital, Masonic Cancer Center, University of Minnesota

Conditions

Acute GVHDAplastic AnemiaFallopian Tube CancerGynecologic CancerHematologic DiseasesLeukemiaLymphoma, Non-HodgkinMetastatic Colorectal Cancer

Phase 1

SGI-110 in Combination With an Allogeneic Colon Cancer Cell Vaccine (GVAX) and Cyclophosphamide (CY) in Metastatic Colorectal Cancer (mCRC)
CompletedNCT01966289
Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsMetastatic Colorectal Cancer
Start: 2014-04-14End: 2020-06-06Updated: 2021-03-30
Intraperitoneal FT536 in Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer
Active, not recruitingNCT06342986
Masonic Cancer Center, University of MinnesotaFallopian Tube Cancer, Gynecologic Cancer, Ovarian Cancer +1
Start: 2024-07-11End: 2027-06-30Updated: 2026-04-02

Phase 2

Sirolimus & Mycophenolate Mofetil as GVHD Prophylaxis in Myeloablative, Matched Related Donor HCT
CompletedNCT00350181
Stanford UniversityAcute GVHD, Hematologic Diseases, Leukemia +1
Start: 2006-08-31End: 2010-04-30Updated: 2021-09-23
Pomalidomide for Lenalidomide for Relapsed or Refractory Multiple Myeloma Patients
TerminatedNCT02188368
OncotherapeuticsMultiple Myeloma
Start: 2014-07-07End: 2020-10-23Updated: 2023-11-03
GVAX Pancreas Vaccine (With CY) and CRS-207 With or Without Nivolumab
CompletedNCT02243371
Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsPreviously Treated Metastatic Adenocarcinoma of the Pancreas
Start: 2015-01-02End: 2017-07-21Updated: 2021-04-06
Study of GVAX (With CY) and Pembrolizumab in MMR-p Advanced Colorectal Cancer
CompletedNCT02981524
Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsMetastatic Colorectal Cancer
Start: 2017-05-26End: 2018-03-20Updated: 2021-02-10

Phase 4

ATG Combined With Cyclophosphamide And Cord Blood Transfusion in Treating Patients With Severe Aplastic Anemia
NCT02838992
Jinan Military General HospitalAplastic Anemia
Start: 2017-02-28End: 2019-07-31Target: 130Updated: 2017-02-01

Related Papers

A feasibility study of combined epigenetic and vaccine therapy in advanced colorectal cancer with pharmacodynamic endpoint
Clinical Epigenetics2021-02-0228 citations
A phase II study of GVAX colon vaccine with cyclophosphamide and pembrolizumab in patients with mismatch repair–proficient (MMR-p) advanced colorectal cancer.
Journal of Clinical Oncology2019-01-297 citations
T cell receptor repertoire features associated with survival in immunotherapy-treated pancreatic ductal adenocarcinoma.
2018-07-12191 citations
Efficacy and safety of pomalidomide as a replacement therapy for lenalidomide for relapsed/refractory multiple myeloma patients refractory to a lenalidomide-containing combination regimen.
Journal of Clinical Oncology2018-05-202 citations
Randomized phase 2 study of the safety, efficacy, and immune response of GVAX pancreas (with cyclophosphamide) and CRS-207 with or without nivolumab in patients with previously treated metastatic pancreatic adenocarcinoma (STELLAR).
Journal of Clinical Oncology2016-05-203 citations
Randomized phase II study of the safety, efficacy, and immune response of GVAX pancreas (with cyclophosphamide) and CRS-207 with or without nivolumab in patients with previously treated metastatic pancreatic adenocarcinoma (STELLAR).
Journal of Clinical Oncology2016-02-0113 citations
Randomized phase II study of the safety, efficacy, and immune response of GVAX pancreas vaccine (with cyclophosphamide) and CRS-207 with or without nivolumab in patients with previously treated metastatic pancreatic adenocarcinoma (STELLAR).
Journal of Clinical Oncology2015-05-209 citations